Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2008-000955-90-IT (EUCTR)	24/04/2007	12/03/2008	Randomized, single-blind, clinical and MRI study for evaluation of safety and efficacy of N-Acetyl Cysteine (NAC) associated with high-dose beta-Interferon in Relapsing-Remitting (RR) multiple sclerosis patients - renac	Randomized, single-blind, clinical and MRI study for evaluation of safety and efficacy of N-Acetyl Cysteine (NAC) associated with high-dose beta-Interferon in Relapsing-Remitting (RR) multiple sclerosis patients - renac	multiple sclerosis MedDRA version: 9.1;Level: HLT;Classification code 10052785;Term: Multiple sclerosis acute and progressive	Product Name: n-acetylcysteine INN or Proposed INN: Acetylcysteine	ISTITUTO C. MONDINO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
2	NCT00203099 (ClinicalTrials.gov)	December 2004	13/9/2005	Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine	A Pilot, Multicenter, Open-label, One-group Study to Explore the Efficacy, Tolerability and Safety of the Combination of Glatiramer Acetate (GA) and N-Acetylcysteine (NAC) in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)	Relapse Remitting Multiple Sclerosis	Drug: Glatiramer Acetate, N-Acetylcysteine	Teva Pharmaceutical Industries	NULL	Completed	18 Years	50 Years	Both	18	Phase 2	Canada